News + Events2019-02-14T10:49:18+00:00

Latest Press Releases

Cadent Therapeutics to Present at the Cowen 40th Annual Health Care Conference

February 26th, 2020|

CAMBRIDGE, Mass., February 26, 2020 – Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Cowen 40th Annual Health Care Conference on Monday, March 2, 2020 at 4:00-4:25 pm ET at the Boston Marriott Copley Place.

Cadent Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

February 19th, 2020|

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:45 pm ET at the Lotte New York Palace.

Cadent Therapeutics Announces Poster Presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

February 6th, 2020|

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that the Company's Cadence-1 study will be highlighted in a poster presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress from February 14-16, 2020 at the InterContinental Miami in Miami, Florida.

Cadent Therapeutics Announces FDA acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)

January 23rd, 2020|

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for CAD-1883...

Load More Posts